@article{oai:repo.qst.go.jp:00047220,
 author = {Nogami, Tsuyoshi and Takano, Harumasa and Arakawa, Ryosuke and Ichimiya, Tetsuya and Fujiwara, Hironobu and Kimura, Yasuyuki and Kodaka, Fumitoshi and Sasaki, Takeshi and Takahata, Keisuke and Suzuki, Masayuki and Nagashima, Tomohisa and Mori, Takaaki and Shimada, Hitoshi and Fukuda, Hajime and Sekine, Mizuho and Tateno, Amane and Takahashi, Hidehiko and Ito, Hiroshi and Okubo, Yoshiro and Suhara, Tetsuya and 野上 毅 and 高野 晴成 and 荒川 亮介 and 一宮 哲哉 and 藤原 広臨 and 木村 泰之 and 小高 文聰 and 佐々木 健至 and 高畑 圭輔 and 鈴木 雅之 and 永嶌 朋久 and 森 崇明 and 島田 斉 and 関根 瑞保 and 舘野 周 and 高橋 英彦 and 伊藤 浩 and 大久保 善朗 and 須原 哲也},
 issue = {5},
 journal = {The International Journal of Neuropsychopharmacology},
 month = {Oct},
 note = {Antidepressants used for treatment of depression exert their efficacy by blocking reuptake at serotonin transporters (5-HTT) and/or norepinephrine transporters (NET). Recent studies suggest that serotonin and norepinephrine reuptake inhibitors that block both 5-HTT and NET have better tolerability than tricyclic antidepressants and may have higher efficacy compared to selective serotonin reuptake inhibitors. Previous positron emission tomography (PET) studies have reported >80% 5-HTT occupancy with clinical doses of antidepressants, but there has been no report of NET occupancy in patients treated with antidepressants. In the present study, we investigated both 5-HTT and NET occupancies by PET using radioligands [11C]DASB and (S,S)-[18F]FMeNER-D2, in six patients, each with major depressive disorder (MDD), using various doses of milnacipran. Our data show that mean 5-HTT occupancy in the thalamus was 33.0% at 50?mg, 38.6% at 100?mg, 60.0% at 150?mg and 61.5% at 200?mg. Mean NET occupancy in the thalamus was 25.3% at 25?mg, 40.0% at 100?mg, 47.3% at 125?mg and 49.9% at 200?mg. Estimated ED50 was 122.5?mg with the dose for 5-HTT and 149.9?mg for NET. Both 5-HTT and NET occupancies were observed in a dose-dependent manner. Both 5-HTT and NET occupancies were about 40% by milnacipran at 100?mg, the dose most commonly administered to MDD patients.},
 pages = {937--943},
 title = {Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [11C]DASB and (S,S)-[18F]FMeNER-D2.},
 volume = {16},
 year = {2012}
}